Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cone Dystrophy Clear all
Completed Phase 1 Interventional

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Color Perception Under LED Red/Green and Green Dominant Light

NCT01927536
View directory record Official record
Conditions
Color Blindness, Acquired
Interventions
White LED Flashlight, Red/Green Green Dominant LED Flashlight
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 66 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CNTF Implants for CNGB3 Achromatopsia

NCT01648452
View directory record Official record
Conditions
Eye Disease, Achromatopsia
Interventions
NT-501 CNTF-releasing implant
Biological
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGA3)

NCT03758404
View directory record Official record
Conditions
Achromatopsia
Interventions
adeno-associated virus vector AAV- CNGA3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

NCT04945772
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jul 21, 2026, 11:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

NCT03326336
View directory record Official record
Conditions
Non-syndromic Retinitis Pigmentosa
Interventions
Gene therapy: GS030-DP AND Medical device: GS030-MD
Combination Product
Lead sponsor
GenSight Biologics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting No phase listed Observational

Adaptive Optics Imaging of Outer Retinal Diseases

NCT05355415
View directory record Official record
Conditions
Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy, Usher Syndromes, Late-Onset Retinal Degeneration, Cone Dystrophy, Cone Rod Dystrophy, Rod Cone Dystrophy, Rod Dystrophy
Interventions
Adaptive optics imaging
Device
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2021 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939
View directory record Official record
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Interventions
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
Drug
Lead sponsor
Ocugen
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

NCT03116113
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIIB112
Biological
Lead sponsor
Biogen
Industry
Eligibility
10 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting No phase listed Observational

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

NCT06491615
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Alcohol Use Disorder and Cannabidiol

NCT05613608
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

NCT04289571
View directory record Official record
Conditions
Cone-Rod Degeneration, Rod-Cone Degeneration
Interventions
VR Mobility Tool
Diagnostic Test
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years to 120 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
View directory record Official record
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

NCT02935517
View directory record Official record
Conditions
Achromatopsia
Interventions
AGTC-402
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 21, 2026, 11:14 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of EnChroma Use in the Emergency Department Setting

NCT04021914
View directory record Official record
Conditions
Color Vision Defects
Interventions
EnChroma glasses
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 21, 2026, 11:14 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

NCT05077956
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
Cerebrospinal and Blood Serum Semaphorin 4A Levels
Diagnostic Test
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 21, 2026, 11:14 AM EDT
Not yet recruiting Early Phase 1 Interventional

Topical CBD Scar Outcomes Study

NCT05650697
View directory record Official record
Conditions
Forehead; Wound
Interventions
Group 1 cannabidiol (CBD) with silicone ointment, Group 2 silicone patch
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

EyeConic: Qualification for Cone-Optogenetics

NCT05294978
View directory record Official record
Conditions
Retinal Dystrophies
Interventions
Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

This Research Study Examines the Effects of Cannabidiol-infused Candy on Reducing the Bacteria Causing Tooth Decay, When Comparing it to a Sugar Free Candy on Adults.

NCT06301113
View directory record Official record
Conditions
Tooth Decay
Interventions
CBD infused candy, Sugar free Candy
Dietary Supplement
Lead sponsor
West Coast University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Jul 21, 2026, 11:14 AM EDT
Active, not recruiting Not applicable Interventional

Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity

NCT05429736
View directory record Official record
Conditions
Incomplete Spinal Cord Injury, Spasticity, Muscle
Interventions
Motor Skill Training (MST), Transcutaneous Spinal Stimulation (TSS)
Behavioral · Device
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 21, 2026, 11:14 AM EDT
Recruiting Phase 3 Interventional

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

NCT05561127
View directory record Official record
Conditions
Bowel; Stricture
Interventions
GIE Medical ProTractX3 TTS DCB, Control
Combination Product · Other
Lead sponsor
GIE Medical
Industry
Eligibility
22 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
32
States / cities
Scottsdale, Arizona • Irvine, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 21, 2026, 11:14 AM EDT